PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7321658

[The placebo problem].

W Reinhard
View original source ↗Export metadata ↓

Abstract

Holding placebo response to be a result of magical happenstance and doctor-patient relationship appears less than satisfying. The important factor of spontaneous development in illness, as "visually" demonstrated by Siemens in 1939, is pointed out. The controlled trial is considered analogous to this method. The conditions for carrying out a controlled trial and the control substances are discussed, the deciding criteria for carrying out a placebo-controlled trial are mentioned. The analysis of a placebo-controlled trial is not detrimental to the patient.

Explore related subjects

Clinical Trials as TopicHumansPhysician-Patient RelationsPlacebosResearch DesignEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

W Reinhard. 1981. [The placebo problem].. https://pubmed.ncbi.nlm.nih.gov/7321658/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1997

Gene therapy for cancer: what have we done and where are we going?

Gene-based therapies for cancer in clinical trials include strategies that involve augmentation of immunotherapeutic and chemotherapeutic approaches. These strategies include ex vivo and in vivo cytokine gene transfer, drug sensitization with genes for prodrug delivery, and the use of drug-resistance genes for bone marrow protection from high-dose chemotherapy. Inactivation of oncogene expression and gene replacement for tumor suppressor genes are among the strategies for targeting the underlying genetic lesions in the cancer cell. A review of clinical trial results to date, primarily in patients with very advanced cancers refractory to conventional treatments, indicates that these treatments can mediate tumor regression with acceptably low toxicity. Vector development remains a critical area for future research. Important areas for future research include modifying viral vectors to reduce toxicity and immunogenicity, increasing the transduction efficiency of nonviral vectors, enhancing vector targeting and specificity, regulating gene expression, and identifying synergies between gene-based agents and other cancer therapeutics.

Clinical Trials as Topic↗